Akt/ERK Inhibitor ONC201 Clinical Trials
2 recruitingDrug
Phase 22Phase 11
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Recurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeRefractory Acute Lymphoblastic Leukemia+3 more
M.D. Anderson Cancer Center120 enrolled1 locationNCT02392572
Recruiting
Phase 2
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+7 more
Ira Winer62 enrolled2 locationsNCT04055649